abstract |
The invention relates to modulating the SIRP.alpha.-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP.alpha. polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia. |